Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $80
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $75 to $80.
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $75 to $80.